Drug Profile
CXB 909
Alternative Names: CXB909; KP 544; KRX-0501Latest Information Update: 27 Jun 2013
Price :
$50
*
At a glance
- Originator Krenitsky Pharmaceuticals
- Developer Keryx Biopharmaceuticals
- Class Antidementias; Nootropics; Pyrimidines; Small molecules
- Mechanism of Action Choline kinase stimulants; Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Neurological disorders